Beam Therapeutics Inc. (BEAM)
$25.13-2.22%Close
BUYRECOVERY · day 6
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $2.6B
- Beta
- 2.20
- P/E (TTM)
- -30.77
- Short % float
- 29.57%
- Days to cover
- 15.3
- SI change
- +6.4%
- 1W
- -2.10%
- 1M
- +4.75%
- vs SPY 1W
- -2.53%
- vs SPY 1M
- +2.69%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 0
- VALUE
- 4
- GROWTH
- 2
- GARP
- 5
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-4.6%
REV YoY-
ROE-7.7%
EPS YoY-
ROA-6.2%
GROSS19
OP-242
NET-55
[VALUATION]
P/E TTM-30.77
P/E FWD-
SECTOR PE-
INDUSTRY PE13.84
P/B2.47
P/FCF-
EV/EBITDA-43.51
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E23.17
ALTMAN Z-
CURR RATIO14.57
ND/EBITDA-
BETA2.20
Company news
FAQ
- What is LOPJLB’s current signal on BEAM?
- LOPJLB’s latest quantitative signal on Beam Therapeutics Inc. (BEAM) is BUY in a RECOVERY regime. Signals are updated daily.
- What market regime is BEAM in?
- Beam Therapeutics Inc. (BEAM) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Beam Therapeutics Inc. (BEAM) do?
- Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell…